Janssen applies for FDA approval for Genmab drug

Teclistamab, which is based on Genmab's duobody technology platform, will now be evaluated by the FDA.

Photo: Tuala Hjarnø / Genmab / PR

Genmab's partner Janssen has applied for approval for its bone marrow cancer treatment teclistamab from the US Food and Drug Administration (FDA).

The application is based on phase I and II results for the drug, which is based on Genmab's Duobody platform and is being developed as a treatment for bone marrow cancer. Genmab and Janssen already have one successful partnership in this indication, in the form of Darzalex.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs